PCPhilippe de Figueiredo Braga Colares

Philippe de Figueiredo Braga Colares

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philippe de Figueiredo Braga Colares has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Agranulocitose secundária à lamotrigina: um relato de caso

    by Eduardo Vilela de Andrade, Lazaro Leonardo Mendes de Oliveira, Felipe Garcia Pereira, Isabela Pimenta Pelucio, Akissy Aline Uchiyama Nomura, Laura Madureira Belissimo, Carolina Bertini Bonini, Vitor Pio de Queiroz, Aquila Marcelle Dias Ferreira, Maria Eduarda Facci de Castro, et al.

    A lamotrigina é uma medicação anticonvulsivante indicada tanto para crises focais quanto generalizadas, para adultos e crianças a partir de 2 anos de idade, apesar de estudos demonstrarem segurança e eficácia de uso a partir de 1 mês de vida (Piña-Garza et al., 2008). É uma droga totalmente absorvida via enteral, metabolizada no fígado e excretada via renal, com meia vida de 12 a 62 horas em adultos. A lamotrigina age inativando canais de sódio voltagem-dependentes dos neurônios e bloqueando a liberação de disparos neuronais repetitivos, além de ter possível ação sináptica ao diminuir a síntese e liberação de aspartato e glutamato de neurônios excitatórios, e, dessa forma, inibir a gênese de convulsões (Mitra-Ghosh et al., 2020). Os principais efeitos adversos da medicação incluem rash cutâneo, que pode acometer até 10% dos pacientes nos primeiros 2 meses de tratamento, cardiológicos, pelo potencial arritmogênico e neurológicos, ao causar sonolência. Os relatos de acometimento hematológico são mais raros, e já incluem leucopenia, neutropenia, trombocitopenia e coagulação intravascular disseminada, que podem ser decorrentes da inibição da diidrofolato-redutase, toxicidade medular direta ou parte da síndrome de hipersensibilidade à droga (Johnston & Uetrecht, 2014). O objetivo deste relato de caso é descrever a ocorrência de agranulocitose decorrente do uso da medicação em uma paciente idosa, com rápida recuperação após a suspensão do medicamento. Também busca ampliar a divulgação de potenciais efeitos adversos que, apesar de raros, são potencialmente graves, de modo que o reconhecimento dessa condição seja mais precoce e o risco de desfechos desfavoráveis, minimizados.

  • Open Access

    ANXIETY, DEPRESSION, AND QUALITY OF LIFE OF NURSES WORKING IN PUBLIC HOSPITALS

    by Felipe Matheus Sant’aNna Aragão, Philippe de Figueiredo Braga Colares, Iapunira Catarina Sant’aNna Aragão, Francisco Prado Reis, José Aderval Aragão

    Nursing is often described as the art of caring, providing holistic patient assistance without time restrictions. However, due to this nature of work, it is common for these professionals to present symptoms of mental illnesses such as anxiety and depression. This results in a reduction in the quality of life at work, directly affecting the efficiency of care provision. This study aimed to verify the presence of anxiety and depression symptoms, as well as the index of quality of life at work among nurses working in the inpatient sector of public hospitals in the city of Aracaju. Among the 128 professionals included in the sample, 46.1% presented anxiety symptoms and 30.5% depression symptoms, according to the HADS scale. Additionally, 66.4% of nurses reported an unsatisfactory quality of life at work index (QLWI). The majority of professionals who presented symptoms of both diseases were female; 17.2% had two employment bonds, and 19.5% reported an unsatisfactory QLWI. Therefore, it is possible to infer that the accumulation of employment bonds and the reduction in quality of life at work may have been determining factors for the development of these symptoms. It is concluded that it is extremely important to improve working conditions, safety, and remuneration, as well as increase the institutional appreciation and recognition of nursing professionals. This would contribute to raising the quality of life indices at work and reducing the need for multiple employment bonds.

  • Open Access

    Thoracic ultrasound: a review of the state-of-the-art

    by Philippe de Figueiredo Braga Colares, Thiago Thomaz Mafort, Felipe Marquesini Sanches, Laura Braga Monnerat, Carlos Augusto Metidieri Menegozzo, Alessandro Wasum Mariani

    Thoracic ultrasound (TUS) is a tool that has become increasingly essential in the daily practice of thoracic medicine. Driven by the need to assess patients during the COVID-19 pandemic, there has been an increase in the use of point-of-care TUS, which has demonstrated several benefits, either as a complement to clinical decision-making for diagnosis or as a real-time guide for procedures, whether as a predictor or measure of treatment response. Here, we present a review of TUS, based on the most recent scientific evidence, from equipment and techniques to the fundamentals of pulmonary ultrasound, describing normal and pathological findings, as well as focusing on the management of lung disease and guidance for invasive thoracic procedures at the bedside. Finally, we highlight areas of perspective and potential lines of research to maintain interest in this valuable tool, in order to improve the diagnostic process and expand the treatment arsenal.


  • Open Access

    Respiratory amyloidosis: a case series from a Brazilian referral center

    by Philippe de Figueiredo Braga Colares, Alfredo Nicodemos Cruz Santana, Rodrigo Abensur Athanazio, Ronaldo Adib Kairalla, Bruno Guedes Baldi


  • Open Access

    Idiopathic pulmonary fibrosis: current diagnosis and treatment

    by Alexandre Franco Amaral1, Philippe de Figueiredo Braga Colares1, Ronaldo Adib Kairalla1

    Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront of new diagnostic algorithms and treatment developments that led to a shift in patients' care in the past decade, indeed influencing the management of fibrotic interstitial lung diseases other than IPF itself. Clinical presentation, pathophysiology, and diagnostic criteria are briefly addressed in this review article. Additionally, evidence regarding the use of antifibrotics beyond the settings of clinical trials, impact of comorbidities, and therapeutic approaches other than pharmacological treatments are discussed in further detail.


  • Open Access

    COVID-19 and pulmonary alveolar proteinosis: an unusual combination

    by Philippe de Figueiredo Braga Colares, Natalia Fernandes da Silva, Ronaldo Adib Kairalla, Bruno Guedes Baldi


  • Open Access

    Tuberculous empyema: combined intrapleural therapy might be an alternative

    by Philippe de Figueiredo Braga Colares, Jennifer Kiara Delgado Rivas, Amanda dos Santos Sciortino, Roberta Karla Barbosa de Sales, Lisete Ribeiro Teixeira


  • Mesothelioma in situ with regressive malignant pleural effusion and an unexpected evolution: A case report

    by Gustavo C. de Almeida, Ubiratan de P. Santos, Yuri de D. M. Parente, Philippe de F. B. Colares, Rafael F. Mizutani, Fabíola del C. Bernardi, Ricardo M. Terra, Mario Terra‐Filho

    Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that originates from hyperplasia and metaplasia of the mesothelial cells that cover the pleural cavity. Previous exposure to asbestos is the main risk factor. Since MPM is often diagnosed at an advanced stage with rapid evolution and resistance to treatment, it is associated with an unfavorable outcome. Mesothelioma in situ (MIS) has been postulated as a preinvasive phase of MPM; however, its diagnostic criteria have been defined only recently. Diagnosis of MIS may represent an opportunity for early therapies with better results, but the optimal approach has not been defined thus far. Here, we report on a case of a 74‐year‐old man with right‐sided pleural effusion and a previous history of occupational exposure to asbestos for 9 years who was diagnosed with MIS after a latency of 36 years. During follow‐up, spontaneous disease regression was observed 5 months after the initial diagnosis; however, it recurred in the form of invasive epithelioid MPM. There is a paucity of literature on MIS and its evolution; however, our case provides relevant knowledge of this unusual behavior, which is important to define follow‐up and therapeutic strategies for future cases.


  • Open Access

    An unusual cause of pleural effusion in a patient with heart failure

    by Daniel Bruno Takizawa, Philippe de Figueiredo Braga Colares, Olívia Meira Dias